[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"angina-patients-with-non-obstructive-coronary-artery-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:angina-patients-with-non-obstructive-coronary-artery-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100562208","phase-1-study-targeting-myocardial-perfusion-and-symptom-relief-in-women-with-sglt2-inhibitors-strong-100562208",false,"NCT06600178","Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)","Innovative Therapy to Treat Women With Angina With Nonobstructive Coronary Artery Disease (ANOCA) and Coronary Microvascular Disease","STRONG","Inclusion Criteria:\n\n* • Female sex.\n\n  * Age ≥18 years.\n  * Willing and able to provide written informed consent.\n  * Signs and symptoms of suspected ischemia prompted referral for further evaluation by cardiac catheterization or CCTA within two years of consent.\n  * No evidence of obstructive epicardial CAD (stenosis \\\u003C50%) of a major epicardial vessel or an FFR ≤0.80 by invasive catheterization or CCTA. Patients who have not undergone cardiac catheterization of CT angiogram within the last 2 years for chest pain can be scheduled for a screening CT angiogram of the coronary arteries to confirm eligibility.\n  * Diagnosis of CMD defined by CFR \\< 2 by CMR\n  * Never on SGLT2i\n\nExclusion Criteria:\n\n* History of non-ischemic cardiomyopathy LVEF \\\u003C40% or hypertrophic cardiomyopathy.\n* History of congestive heart failure, severe pulmonary disease, liver disease\n* History of acute coronary syndrome (ACS) within previous 30 days\n* Stroke within the last 180 days or intracranial hemorrhage at any time.\n* Severe valvular disease\n* Life expectancy \\\u003C3 years, due to non-cardiovascular comorbidity.\n* Pregnancy or women who are breast-feeding\n* Type 1 diabetes mellitus\n* Symptomatic hypotension or systolic BP \\>95 mmHg on 2 consecutive measurements\n* Active malignancy requiring treatment at the time of visit\n* Severe (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2 by CKD-EPI), unstable, or rapidly progressing renal disease at the time of randomization\n* History of recurrent UTI\u002Fbladder\u002Fkidney infections\n* Asthma with ongoing wheezing\n* Known or suspected broncho-constrictive or bronchospastic lung disease (ARDS, emphysema)\n* Greater than first degree heart block\n* Implanted cardiac device\n* Profound sinus bradycardia (heart rate \\\u003C40 beats per minute)\n* Atrial fibrillation or supraventricular arrhythmias at time of imaging\n* Known intolerance of nitrates (other than hypotension)\n* History of reaction to iodinated contrast agents","FEMALE","18 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The goal of this clinical trial is to that Sodium-glucose cotransporter 2 inhibitors treatment will improve Coronary Microvascular Disease with anginal symptoms associated with non-obstructive coronary disease in women. The main questions it aims to answer are:\n\nAim 1: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves coronary microvascular disease in women with no evidence of epicardial obstructive coronary artery disease.\n\nAim 2: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves angina symptoms and other quality of life measurements associated with the improvement of CFR.\n\nAIM 3: Identify the effect of Sodium-glucose cotransporter 2 inhibition on inflammation pathways and markers of systemic Research will compare Brezavvy to placebo\n\nParticipants will:\n\n* Take study drug or placebo for 12 weeks\n* Stress Cardiac magnetic resonance imaging\n* 12 lead electrocardiograms\n* Complete questionnaires",[27,28,29],"Angina Patients With Non-obstructive Coronary Artery Disease","Coronary Microvascular Disease","Coronary Microvascular Dysfunction (CMD)",[31,32,33,34,35,36],"Angina","ANOCA","Non-obstructive Coronary Artery Disease","CMD","Non-Obstructive CAD","Chest Pain in Women","RECRUITING","2025-10-27",{"date":40,"type":41},"2025-10-29","ACTUAL",{"date":43,"type":41},"2025-06-27",{"date":45,"type":21},"2026-10",{"name":47,"class":48},"University of Virginia","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":49},"100588960","inorganic-nitrate-as-a-treatment-for-anoca-no-anoca-100588960","NCT06948201","Inorganic Nitrate as a Treatment for ANOCA: NO-ANOCA","NO-ANOCA","Inclusion Criteria:\n\n* Age ≥18 years.\n* Female sex.\n* Willing and able to provide written informed consent.\n* Signs and symptoms of suspected ischemia prompted referral for further evaluation by cardiac catheterization or CCTA within two years of consent.\n* No evidence of obstructive epicardial CAD (stenosis \\>50%) of a major epicardial vessel or an FFR ≤0.80 by invasive catheterization or CCTA. Patients who have not undergone cardiac catheterization of CT angiogram within the last 2 years for chest pain can be scheduled for a screening CT angiogram of the coronary arteries to confirm eligibility.\n* Impaired coronary flow reserve (cut-off values depending on methodology use between ≤2.0 and ≤2.5 by stress testing PET\u002FCMR or Invasive assessment) or Abnormal index of coronary microcirculatory resistance (e.g., IMR \\> 25)\n* SGLT2i Naïve\n\nExclusion Criteria:\n\n* History of non-ischemic cardiomyopathy LVEF \\\u003C40% or hypertrophic cardiomyopathy.\n* History of congestive heart failure, severe pulmonary disease, liver disease\n* History of acute coronary syndrome (ACS) within previous 30 days\n* Stroke within the last 180 days or intracranial hemorrhage at any time.\n* Severe valvular disease\n* Life expectancy \\\u003C3 years, due to non-cardiovascular comorbidity.\n* Pregnancy or women who are breast-feeding\n* Type 1 diabetes mellitus\n* Symptomatic hypotension or systolic BP\\\u003C95 mmHg on 2 consecutive measurements\n* Active malignancy requiring treatment at the time of visit\n* Severe (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2 by CKD-EPI), unstable, or rapidly progressing renal disease at the time of randomization\n* History of recurrent UTI\u002Fbladder\u002Fkidney infections\n* Asthma with ongoing wheezing\n* Known or suspected bronchoconstrictive or bronchospastic lung disease (ARDS, emphysema)\n* Greater than first degree heart block\n* Implanted cardiac device\n* Profound sinus bradycardia (heart rates\\\u003C40 beats per minute)\n* Atrial fibrillation or supraventricular arrhythmias at time of imaging\n* Known intolerance of nitrates (other than hypotension)\n* History of reaction to iodinated contrast agents\n* Any orthopedic, neurological, or other condition that prevents participant from exercising\n* Individuals currently taking nitroglycerine (or inorganic nitrates), PDE-5 inhibitors (ex: Cialis, Viagra), and xanthine oxidase inhibitors (ex: Allopurinol)\n* Smokers within the last 5 years\n* Prisoners\n* Cognitively impaired individuals\n* Non-English Speaking",{"count":58,"type":21},8,[60],"NA","The purpose of this study is to see if inorganic nitrate in the form of beetroot juice helps blood flow and physical fitness in women with ANOCA and CMD. The main questions it aims to answer are:\n\nAIM 1: Test the hypothesis that fourteen days of nitrate rich beetroot juice will increase cardiac perfusion and improve quality of life compared to placebo.\n\nAIM 2: Test the hypothesis that fourteen days of nitrate rich beetroot juice will increase physical fitness and reduce angina and dyspnea symptoms compared to placebo.\n\nExploratory AIM 3: Test the hypothesis that fourteen days of nitrate rich beetroot juice will improve vascular health and function.\n\nParticipants will:\n\n* Take study beverage for 4 weeks total.\n* Stress Cardiac magnetic resonance imaging and 12 lead electrocardiograms\n* Complete questionnaires\n* Cycling exercise test\n* Non invasive vascular testing\n* Blood draws",[29,27],[64,32,33,34,35,36],"angina","NOT_YET_RECRUITING","2025-04-23",{"date":68,"type":41},"2025-04-29",{"date":70,"type":21},"2025-05",{"date":72,"type":21},"2026-06",{"name":47,"class":48},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":81,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":49},"100554788","coronary-microvascular-dysfunction-in-angina-patients-with-non-obstructive-coronary-artery-disease-anoca-cmd-100554788","NCT06503640","Coronary Microvascular Dysfunction in Angina Patients With Non-obstructive Coronary Artery Disease (ANOCA-CMD)","Coronary Microvascular Dysfunction in Angina Patients With Non-obstructive Coronary Artery Disease","Inclusion Criteria:\n\n* presence of stable anginal symptoms, a clinical indication for invasive coronary angiography, and no hemodynamically significant epicardial coronary artery disease, defined as fractional flow reserve (FFR) \\>0.80\n\nExclusion Criteria:\n\n1. acute myocardial infarction\n2. significant valvular heart disease\n3. advanced chronic kidney disease\n4. patients with significant epicardial coronary artery stenosis (\\>70% in major vessels by diagnostic coronary angiography) needing percutaneous coronary intervention\n5. patients unable to provide written informed consent","ALL",{"count":83,"type":21},100,"OBSERVATIONAL","The goal of this observational study is to explore the incidence and effect on prognosis of coronary microvascular dysfunction in patients present of stable anginal symptoms, a clinical indication for invasive coronary angiography, and no hemodynamically significant epicardial coronary artery disease, defined as fractional flow reserve (FFR) \\>0.80.",[27,87,88],"Coronary Microvascular Dysfunction","Index of Microvascular Resistance","2024-07-10",{"date":91,"type":41},"2024-07-16",{"date":93,"type":41},"2023-07-01",{"date":95,"type":21},"2025-12-31",{"name":97,"class":48},"China-Japan Friendship Hospital"]